Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Besponsa

Chemical Nameinotuzumab ozogamicin
Dosage FormInjection (intravenous; 0.9 mg/vial)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyPfizer
Approval Year2017

Indication

  • Indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Last updated on 4/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Besponsa (inotuzumab ozogamicin) Prescribing Information.2018Pfizer
Document TitleYearSource
Australian public assessment report for Inotuzumab ozogamicin. 2019Australian Government: Department of Health
Final economic guidance report. inotuzumab ozagamycin (Besponsa) for acute lymphoblastic leukemia.2018CADTH
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.2018NICE
Final clinical guidance report: Inotuzumab ozagamycin (Besponsa) for acute lymphoblastic leukemia. 2018CADTH
Public assessment report: Besponsa. 2017EMA
Document TitleYearSource
Efficacy and safety of inotuzumab ozogamicin (CMC-544) for the treatment of relapsed/ refractory acute lymphoblastic leukemia and non-hodgkin lymphoma: a systematic review and meta-analysis. 2021Clinical Lymphoma, Myeloma & Leukemia
Document TitleYearSource
Pediatric acute lymphoblastic leukemia, version 2.2020. 2020Journal of the National Comprehensive Cancer Network
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. 2020Journal for ImmunoTherapy of Cancer
NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. 2017Journal of the National Comprehensive Cancer Network